Oculis Holding AG (OCS)

NASDAQ
Currency in USD
19.480
-0.250(-1.27%)
Closed·
After Hours
19.4800.000(0.00%)
·
OCS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
OCS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
19.31019.700
52 wk Range
10.79023.080
Key Statistics
Edit
Prev. Close
19.48
Open
19.684
Day's Range
19.31-19.7
52 wk Range
10.79-23.08
Volume
18.12K
Average Vol. (3m)
35.74K
1-Year Change
65.79%
Book Value / Share
3.47
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
OCS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
37.469
Upside
+92.34%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings downwards for the upcoming period

Oculis Holding AG News & Analysis

Show more

Oculis Holding AG Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.

Compare OCS to Peers and Sector

Metrics to compare
OCS
Peers
Sector
Relationship
P/E Ratio
−8.5x−1.2x−0.5x
PEG Ratio
0.190.000.00
Price / Book
5.4x1.5x2.6x
Price / LTM Sales
1,162.0x14.6x3.0x
Upside (Analyst Target)
81.6%93.5%51.9%
Fair Value Upside
Unlock−0.6%8.9%Unlock

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 37.469
(+92.34% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-0.69 / -0.46
Revenue / Forecast
285.00K / 520.00K
EPS Revisions
Last 90 days

OCS Income Statement

People Also Watch

24.07
SNDA
+0.04%
27.60
GIGNY
0.00%
160.00
STZ
-0.35%
4.26
HLPPY
-1.16%

FAQ

What Is the Oculis Holding (OCS) Stock Price Today?

The Oculis Holding stock price today is 19.48

What Stock Exchange Does Oculis Holding Trade On?

Oculis Holding is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Oculis Holding?

The stock symbol for Oculis Holding is "OCS."

What Is the Oculis Holding Market Cap?

As of today, Oculis Holding market cap is 1.06B.

What Is Oculis Holding's Earnings Per Share (TTM)?

The Oculis Holding EPS (TTM) is -2.38.

From a Technical Analysis Perspective, Is OCS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Oculis Holding Stock Split?

Oculis Holding has split 0 times.

How Many Employees Does Oculis Holding Have?

Oculis Holding has 49 employees.

What is the current trading status of Oculis Holding (OCS)?

As of Jun 20, 2025, Oculis Holding (OCS) is trading at a price of 19.48, with a previous close of 19.48. The stock has fluctuated within a day range of 19.31 to 19.70, while its 52-week range spans from 10.79 to 23.08.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.